Alpha 2.0
Login Register
» Journals » J Immunother

Journal of Immunotherapy

The Journal of Immunotherapy is a leading scientific publication dedicated to advancing the field of immunotherapy. It features cutting-edge research and clinical studies on the development and application of immunotherapeutic approaches for the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. With a focus on novel immunotherapeutic strategies, this journal serves as a valuable resource for researchers, clinicians, and industry professionals in the field of immunotherapy.
Details
Abbr. J Immunother
Start 1997
End Continuing
Frequency Nine no. a year, 2008-
p-ISSN 1524-9557
e-ISSN 1537-4513
Country United States
Language English
Specialty Allergy & Immunology
Metrics
h-index / Ranks: 2815 106
SJR / Ranks: 2603 1263
CiteScore / Ranks: 2534 7.50
JIF / Ranks: 2352 3.9
Recent Articles
1.
RBBP8 Is a Prognostic Biomarker Associated With Response to Immune Checkpoint Inhibitors in Advanced Gastric Cancer
Nakashima T, Matsumoto R, Tanoue K, Nakayama C, Sameshima K, Hozaka Y, et al.
J Immunother . 2025 Mar; PMID: 40033813
The current biomarkers for immune checkpoint inhibitor (ICI) therapy have several limitations, and new ones are being explored. Retinoblastoma-binding protein 8 (RBBP8) is associated with tumor-infiltrating immune cells (TIIC) and...
2.
The Impact of Chronic Obstructive Pulmonary Disease on Immune Checkpoint Inhibitor Effectiveness in Non-small Cell Lung Cancer: A Population Health Study
Chan S, Pond G, Goffin J
J Immunother . 2025 Feb; PMID: 39976181
Chronic obstructive pulmonary disease (COPD) and lung cancer are associated diseases. COPD confers a negative prognosis in NSCLC, but the clinical benefit of immune checkpoint inhibitors (ICI) in this population...
3.
Multi-institutional Analysis of Immune-Oncology Combination Therapy for Metastatic MiT Family Translocation Renal Cell Carcinoma
Ged Y, Touma A, Meza Contreras L, Elias R, Van Galen J, Cupo O, et al.
J Immunother . 2025 Feb; 48(3):113-117. PMID: 39901604
Metastatic translocation renal cell carcinomas (mtRCCs) are rare and aggressive tumors with limited treatment options. Recent studies demonstrated promising activity of immune-oncology (IO) combinations in mtRCC. However, the effectiveness of...
4.
Poly (ADP-Ribose) Polymerase 1 Induces Cyclic GMP-AMP Synthase-stimulator of Interferon Genes Pathway Dysregulation to Promote Immune Escape of Colorectal Cancer Cells
Xia J, Shen Y, Jiang Q, Li X, Yan Y, Xu Z, et al.
J Immunother . 2025 Jan; 48(2):35-45. PMID: 39787528
Colorectal cancer (CRC) ranks third globally in cancer incidence and mortality, posing a significant human concern. Recent advancements in immunotherapy are noteworthy. This study explores immune modulation for CRC treatment....
5.
Secondary Hemophagocytic Lymphohistiocytosis Syndrome Developing in a Patient With Chronic Lymphocytic Leukemia Under a Long-term Ibrutinib Therapy: A Case Report and Literature Review
Gao L, Wang L, Wang B, Wang Q, Cen X, Dong Y
J Immunother . 2024 Dec; 48(3):109-112. PMID: 39726283
Secondary hemophagocytic lymphohistiocytosis (HLH) syndrome, a fatal disorder characterized by NK/T-cell deficiency, cytokine storm, and organ damage, is rare in chronic lymphocytic leukemia (CLL). Ibrutinib, the first generation of irreversible...
6.
Comparison of Antitumor Effects of Combinations of Immune Checkpoint Inhibitors With Dendritic Cells Intratumorally Injected into Irradiated Mouse Adenocarcinoma
Park G, Son W, Lee H, Koh E, Kang H, Song J, et al.
J Immunother . 2024 Dec; 48(3):89-96. PMID: 39726268
Dendritic cells (DCs) are specialized immune cells that play a crucial role in presenting antigens and activating cytotoxic T lymphocytes to combat tumors. The immune checkpoint receptor programmed cell death-1...
7.
15-Deoxy-Δ-12,14-Prostaglandin J2 Represses Immune Escape of Lung Adenocarcinoma by Polarizing Macrophages Through Epidermal Growth Factor Receptor/Ras/Raf Pathway
Jiang F, Yang X, Shan L, Miao H, Shi C
J Immunother . 2024 Dec; PMID: 39711151
Lung adenocarcinoma (LUAD) is a widespread and deadly form of cancer. Prostaglandin 15-deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) possesses antioxidant, anti-inflammatory, and anticancer properties. However, it is unclear whether this effect on LUAD...
8.
Efficacy and Safety of Immune Checkpoint Inhibitors on Advanced Cervical Cancer: A Systematic Review and Meta-analysis
Wang W, Bi X, Feng Y, Ming X, Saina G, Kun W, et al.
J Immunother . 2024 Dec; 48(2):78-88. PMID: 39635970
This study aims to evaluate the efficacy and safety of immune checkpoint inhibitors (ICIs) in patients with histologically proven advanced cervical cancer. MEDLINE (through PubMed), Web of Science, Embase, and...
9.
Machine Learning-enhanced Signature of Metastasis-related T Cell Marker Genes for Predicting Overall Survival in Malignant Melanoma
Fan C, Li Y, Jiang A, Zhao R
J Immunother . 2024 Nov; 48(3):97-108. PMID: 39506915
In this study, we aimed to investigate disparities in the tumor immune microenvironment (TME) between primary and metastatic malignant melanoma (MM) using single-cell RNA sequencing (scRNA- seq ) and to...
10.
Brief Communication: Combination of an MIP3α-Antigen Fusion Therapeutic DNA Vaccine With Treatments of IFNα and 5-Aza-2'Deoxycytidine Enhances Activated Effector CD8+ T Cells Expressing CD11c in the B16F10 Melanoma Model
Fessler K, Zhang J, Sandhu A, Hui Y, Kapoor A, Ayeh S, et al.
J Immunother . 2024 Oct; 48(1):1-5. PMID: 39397434
Previous studies in the B16F10 mouse melanoma model have demonstrated that combining a DNA vaccine comprised of regions of gp100 and tyrosinase-related protein 2 fused to macrophage-inflammatory protein 3-alpha (MIP3α)...